Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer Journal Article

   

Authors:	Navitski, A.; Al-Rawi, D. H.; Liu, Y.; Rubinstein, M. M.; Friedman, C. F.; Rampal, R. K.; Mandelker, D. L.; Cadoo, K.; O'Cearbhaill, R. E.
Article Title:	Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
Abstract:	Poly(ADP-ribose) polymerase inhibitors (PARPi) are FDA approved as frontline maintenance for BRCA-associated advanced stage high-grade ovarian cancer (HGOC), having demonstrated an unprecedented improvement in relapse-free survival. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are rare toxicities of PARPi. We describe three patients with germline BRCA-associated (gBRCA+) HGOC and alterations in AML driver genes. Although none evidenced overt hematologic malignancy, PARPi maintenance was cautiously considered given the potential risk of MDS/AML. A better understanding of the role of clonal hematopoiesis in the subsequent development of PARPi-associated MDS/AML will improve management of this patient population.
Keywords:	ovarian cancer; syndrome; brca mutation; acute myeloid leukemia; myelodysplastic; parp inhibitors
Journal Title:	Gynecologic Oncology Reports
Volume:	38
ISSN:	2352-5789
Publisher:	Elsevier B.V.
Date Published:	2021-11-01
Start Page:	100873
Language:	English
ACCESSION:	WOS:000710109400002
DOI:	10.1016/j.gore.2021.100873
PROVIDER:	wos
PMCID:	PMC8651772
PUBMED:	34926756
Notes:	Article -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/190700